OR WAIT null SECS
January 31, 2024
In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.
September 28, 2023
The European Commission has granted approval for Tyruko (natalizumab), a biosimilar developed by Polpharma Biologics for treating multiple sclerosis.
July 27, 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.
July 05, 2023
When evaluating a drug’s risk assessment for elemental impurities, one must consider all aspects of its lifecycle.
May 31, 2023
Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.
May 24, 2023
Alvotech and Advanz Pharma have signed a strategic partnership agreement for the supply and commercialization of five biosimilar candidates in Europe.
May 12, 2023
The new partnership between Sandoz, a Novartis division, and Just – Evotec Biologics will aim to develop and manufacture multiple biosimilars.
March 17, 2023
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
March 02, 2023
Lilly will cap insulin prices for patients with and without insurance at $35 per month.
February 13, 2023
The BLA includes a comprehensive analytical and clinical data package, including data from the Phase I/III ROSALIA study.